ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Feasibility and effectiveness of the novel HemoClear microfiltration cell-salvage system in cesarean sections in South Africa.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility and effectiveness of the novel HemoClear microfiltration cell-salvage system in cesarean sections in South Africa.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo test the feasibility and effectiveness of implementing the HemoClear microfiltration cell-salvage system for cesarean sections in South Africa.
methodsWe conducted a prospective experimental single-arm feasibility study collecting and processing blood from 20 adult women undergoing cesarean section in Pelonomi Tertiary Hospital, Bloemfontein. Samples obtained from the blood salvaged during the cesarean section before (baseline) and after (concentrate and filtrate) the cell-salvage procedure were tested for cellular, protein, electrolyte, and metabolic parameters, as well as blood coagulation and bacterial or amniotic fluid contamination.
resultsMedian erythrocyte recovery using the HemoClear device was 75.5% (interquartile range [IQR], 63.8%-94.3%). An average volume of 826 ± 146 mL was processed in 15.3 ± 6.3 min, resulting in 266 ± 116 mL of cell concentrate. The filtration procedure washed away >75% of the α-fetoprotein content in the concentrate, resulting in a median recovery of 24.0% (IQR, 21.4%-35.9%). Bacterial contamination was mostly consistent between baseline and concentrate for each patient and resulted mainly from normal skin flora. In six patients, nonskin species were detected.
conclusionThis study shows the HemoClear system's adaptability to resource-constrained environments, which opens the door for broader adoption of its use in similar resource-constrained settings. The HemoClear cell-salvage device is safe and efficient for intraoperative use in obstetric hemorrhage cases and can play an essential role in patient blood management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.